GlassScriptPhysician profile
Sybil L Dundon
NPI 1467081851
$2,971.56
in general payments reported to CMS, 2019-2025
27 companies · $898 in 2025
The $898 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $180 · 2022: $379 · 2023: $751 · 2024: $764 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,390 · Education: $21.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.40 |
| Education | $21.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,766.12 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.91 | 2021-2025 | Entyvio, Eohilia |
| Evoke Pharma, INC. | $154.48 | 2023 | Gimoti |
| Intercept Pharmaceuticals, INC. | $95.86 | 2022-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.34 | 2023-2024 | Xifaxan, Plenvu |
| Braintree Laboratories, INC. | $75.15 | 2022-2025 | Sutab, Suflave |
| Genzyme Corporation | $47.46 | 2022-2024 | |
| Lilly USA, LLC | $43.49 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $41.34 | 2022-2023 | Linzess |
| Qol Medical, LLC | $38.79 | 2022-2025 | Sucraid |
| Ardelyx, INC. | $38.75 | 2023-2024 | Ibsrela |
| Vivus LLC | $36.19 | 2025 | Qsymia |
| Ferring Pharmaceuticals INC. | $35.76 | 2024-2025 | Clenpiq, Rebyota |
| Madrigal Pharmaceuticals | $34.48 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $32.59 | 2024-2025 | Zenpep |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $30.90 | 2023 | Zeposia |
| Janssen Biotech, INC. | $25.33 | 2024 | Stelara |
| Amgen INC. | $23.78 | 2023 | Amjevita |
| Celltrion USA INC. | $21.82 | 2024 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $19.87 | 2023 | Dupixent |
| Medtronic, INC. | $19.70 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.54 | 2024 | Bylvay |
| Merck Sharp & Dohme LLC | $16.14 | 2024 | Dificid |
| Redhill Biopharma INC. | $14.56 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.87 | 2022 | |
| Novo Nordisk INC | $13.60 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $11.74 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sybil Dundon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.